About BBM
Company Profile
Belief BioMed Inc. (BBM) is a globally innovative biotech company that integrates the development, manufacturing and clinical application of gene therapy products. The
company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology.
BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process,
and has established the commercial production platform for gene therapy drugs in China. The company has been building up its capabilities in a variety of fields including
novel adeno-associated virus (AAV) capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinical-grade vector manufacturing
process. It has also established an extensive R&D pipeline covering a wide range of unmet medical needs in different therapeutic areas such as hemophilia, DMD,
Parkinson's disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted IND filings. The Biologics License Application (BLA) of a gene
therapy for the treatment of adult patients with hemophilia B, BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been approved by the NMPA of China.
BBM-H901 is the first approved hemophilia B gene therapy in China. Previously, it was granted Breakthrough Therapy Designation (BTD), and its NDA was granted a Priority
Review Designation, by the China Center for Drug Evaluation (CDE), NMPA. BBM-H901 has also received an Orphan Drug Designation (ODD) and Rare Pediatric Disease
Designation (RPDD) from the U.S. Food and Drug Administration (FDA). The clinical study results for this product have been published in two prestigious international
journals - The Lancet Haematology and the New England Journal of Medicine - and were also announced in an oral presentation at the ISTH 2024 Congress, as well as in a
poster presentation at the ASH 2024 Conference.
Management Team
Dr. Xiao Xiao
Co-founder
Chairman & CSO
Dr. Jane Zheng
Co-founder
CEO
Dr. Zengmin Du
VP, CMC
Dr. Wei Jiang
VP, Operation
Zuquan Xie
VP, Commercial
Our Vision
To be a global leader in gene therapy with
innovative treatments for patients worldwide.
Our Mission
To make cutting-edge gene therapy
drugs that are accessible and affordable.
Key Milestones
Awards & Recognitions
Since its establishment, Belief BioMed has increasingly gained recognition from the industry for its comprehensive strength. By 2024, it has won approximate 40 various corporate awards, including Hurun 2024 Global Unicorn List, the 2023 Shanghai Key Service Unicorn Enterprises, the 2022 China Unicorn Enterprises, the 2022 Top 100 Shanghai Hard Core Technology Enterprises, the Excellence Award in the 2022 National Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology of China. Moving forward, Belief BioMed will continue to forge ahead with a steadfast commitment and an unwavering dedication to becoming a global leader in gene therapy development, so as to bring more innovative treatments for patients around the world.